Ms Olivia CeulemansSenior Business Development Manager
Mr Jujhar ChimaBusiness Development Alliance Managers
Debiopharm International SA
Dr Fabien SebilleDirector Business Development, Licensing Marketing & Communication
Dr Fabrice ParadiesDirector Industrial Business Develpment & Global Commercial Alliances
Dr. M. Newzella GmbH
Dr. M. Newzella GmbH is an international personnel and business consulting company active within the fields of pharmaceuticals and health care and specializing in the areas of Executive Search, Merger & Acquisition and Product & Licensing.
Thanks to its 35 years of branch experience, Dr. Newzella Consulting has built up an extensive international network of excellent business contacts and has far-reaching knowledge of both companies and markets to supports its clients with individual, flexible and high performance services.
Dr Christoph NewzellaManaging Partner & Director Management Consulting
Dr Matthias NewzellaManaging Partner, Director Management Consulting & Head of Executive Search
Ms Susanna VeraALLIANCE MANAGEMENT DIRECTOR
Mr ENRIC TURMOSenior Licensing Manager
Ethypharm is a rapidly growing specialty pharma company with nascent commercial operations, an expanding portfolio of marketed products, a unique drug development expertise and a broad and advanced pipeline.
Ethypharm now incorporating Martindale Pharma of the UK focuses on pain management and treatment for addiction, particularly opioids and alcohol use disorder; with the current short-term goal to commercialize its own or in-licensed drugs in a number of European countries.
In other therapeutic areas, mainly oncology, Ethypharm has a strong capability in developing and manufacturing specific and "complex" drug formulations in order to market them through global or local partners.
Ethypharm’s headquarters are located in Paris, France and has a very strong affiliate in the UK, it owns two manufacturing plants in France, one in China, and an affiliate in the USA.
Ethypharm is actively seeking:
• Licensing-in/acquisition opportunities in pain and addiction (to opioids, alcohol, tobacco) , critical care, complex generics, brands, late stage NCEs, Steriles/Injectables, Hospital products);